Solid Biosciences (SLDB) Q3 2026 earnings summary

Executive summary

• SGT-003 Phase 1/2 and Phase 3 trials advanced; 53 INSPIRE DUCHENNE participants had received treatment, and an FDA meeting on preliminary data and a potential accelerated-approval pathway was scheduled for late Q4 2026.

• No commercial product revenue to date; losses are expected to continue, with September 30 liquidity projected to fund operations into H1 2028.

Financial highlights

• Q3 2026 operating expenses were $57.7M, up 20.0% YoY; net loss was $53.9M versus $45.8M, and loss per share was $0.36 versus $0.48.

• 9M 2026 operating expenses were $172.3M, up 32.8% YoY; net loss was $165.5M versus $124.5M, and loss per share was $1.23 versus $1.46.

• Cash, cash equivalents and available-for-sale securities totaled $348.9M at September 30, 2026, excluding $1.3M restricted cash; no debt was outstanding.

• Q3 R&D was $43.6M versus $38.9M and G&A was $14.1M versus $9.2M; increases reflected personnel and SGT-003/SGT-212 manufacturing and clinical or research costs.

Outlook and guidance

• Cash and available-for-sale securities were expected to fund operating expenses and capital needs into H1 2028; additional funding will be needed to continue beyond then.

• R&D and G&A expenses are expected to rise as trials enroll and advance, manufacturing scales, and pipeline and commercial-readiness work continues.

• SGT-212 initial data were anticipated in Q1 2027, subject to enrollment; SGT-501 first dosing was anticipated by year-end 2026, with initial safety data in H1 2027, subject to enrollment.

• FDA meeting minutes will inform a subsequent update on SGT-003 regulatory discussions.